Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Innoviva, Inc.INVA · Entity 4679 | Sr VP & Chief Business Officer | November 20, 2017 | November 22, 2017 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | Chief Financial Officer | May 14, 2024 | May 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Innoviva, Inc.
Report date November 20, 2017 · Filed November 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 279,422 |
Reported balance
After 2017-11-20 transaction · row 1
1 source rowRow 1 · 2017-11-20 · Tax withholding · Disposed 4,470 · Balance 279,422 F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
Viracta Therapeutics, Inc.
Report date May 14, 2024 · Filed May 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2034-05-14 | Direct | 500,000 |
Reported balance
After 2024-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-14 · Grant · Acquired 500,000 · Balance 500,000 F1: Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of the Vesting Commencement Date (as defined below) and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider in accordance with the Company's 2021 Inducement Equity Incentive Plan through each such date. The Vesting Commencement Date is May 13, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of the Vesting Commencement Date (as defined below) and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider in accordance with the Company's 2021 Inducement Equity Incentive Plan through each such date. The Vesting Commencement Date is May 13, 2024.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AtaiBeckley Inc.
Report date September 11, 2026 · Filed September 11, 2026
Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.06 · Expires 2036-03-11 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-11 · Disposition to issuer · Disposed 1,275,000 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-11 · Disposition to issuer · Disposed 285,000 · Balance 0 F3: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
F3: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerRestricted Stock Units · Derivative | 285,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-036385 · form4.xml · derivative · entry 2 Faerm Michael E. · CIK 0001647141 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 285,000 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). F3 · price: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). F3 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 1,275,000 | Not disclosed Strike: $4.06 | Not disclosed |
DisclosureSEC source: 0001140361-26-036385 · form4.xml · derivative · entry 1 Faerm Michael E. · CIK 0001647141 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,275,000 shares Expires 2036-03-11 F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 21:01 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | GrantRestricted Stock Units · Derivative | 285,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-009412 · form4.xml · derivative · entry 2 Faerm Michael E. · CIK 0001647141 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires not disclosed F2 · derivative.exercise_price: The restricted stock units vest (subject to continued service through each such vesting date) in four equal annual instalments on each of the first four anniversaries of March 11, 2026. F2 · derivative.exercise_date: The restricted stock units vest (subject to continued service through each such vesting date) in four equal annual instalments on each of the first four anniversaries of March 11, 2026. F2 · derivative.expiration_date: The restricted stock units vest (subject to continued service through each such vesting date) in four equal annual instalments on each of the first four anniversaries of March 11, 2026. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 21:01 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | GrantStock Option · Derivative | 1,275,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001140361-26-009412 · form4.xml · derivative · entry 1 Faerm Michael E. · CIK 0001647141 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,275,000 Underlying: Common Stock · 1,275,000 shares Expires 2036-03-11 F1 · derivative.exercise_date: The stock option vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on March 11, 2027 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 14, 2024 Filed May 16, 2024 16:26 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000950170-24-061112 · ownership.xml · derivative · entry 1 Faerm Michael E. · CIK 0001647141 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of the Vesting Commencement Date (as defined below) and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider in accordance with the Company's 2021 Inducement Equity Incentive Plan through each such date. The Vesting Commencement Date is May 13, 2024. Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 21:42 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 4,470 | $13.17 | $58,869.90 |
DisclosureSEC source: 0001179110-17-014569 · edgar.xml · nonDerivative · entry 1 Faerm Michael E. · CIK 0001647141 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,422 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 20:35 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 3,179 | $12.28 | $39,038.12 |
DisclosureSEC source: 0001179110-17-011727 · edgar.xml · nonDerivative · entry 1 Faerm Michael E. · CIK 0001647141 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,892 F1 · shares: The shares were withheld by the Company to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. Read SEC document |
| May 20, 2017 Filed May 23, 2017 20:17 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 3,176 | $11.86 | $37,667.36 |
DisclosureSEC source: 0001179110-17-007838 · edgar.xml · nonDerivative · entry 1 Faerm Michael E. · CIK 0001647141 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,071 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. F2 · balance_after: Includes 2,500 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2017. Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 21:29 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 5,860 | $12.04 | $70,554.40 |
DisclosureSEC source: 0001179110-17-002897 · edgar.xml · nonDerivative · entry 1 Faerm Michael E. · CIK 0001647141 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,747 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 01:41 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 133,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001096 · edgar.xml · nonDerivative · entry 1 Faerm Michael E. · CIK 0001647141 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,607 F1 · shares: Includes 66,698 shares of common stock granted pursuant to a time-based restricted stock award (RSA). Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2018, and 6.25% of the shares subject to the RSA shall vest quarterly thereafter on the Issuer's standard vesting dates until February 20, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · shares: Includes shares of common stock granted pursuant to a performance-based restricted stock award (PSA). The shares vest pursuant to the PSA over a two-year and three-year performance period upon, and subject to a formula related to, the Issuer's achievement of certain levels of relative total shareholder return (TSR). The "target" number of shares that may vest is 33,350 but the actual number of shares that may vest will range from 0 to 66,700 shares based on the Issuer's relative TSR over the performance periods. Subject to achievement of the performance-based vesting conditions, (i) two-thirds of the shares eligible to vest based on achievement for the two-year performance period will vest on February 20, 2019 and the remaining one-third of such shares will vest on February 20, 2020 and (ii) the share eligible to vest based on achievement for the three-year performance period will vest on February 20, 2020, in each case, (continued in Footnote 3) F3 · shares: (continued from Footnote 2) provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 22:43 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 2,893 | $10.91 | $31,562.63 |
DisclosureSEC source: 0001179110-16-031972 · edgar.xml · nonDerivative · entry 1 Faerm Michael E. · CIK 0001647141 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,209 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. F2 · balance_after: Includes 232 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.